NEUP
Neuphoria Therapeutics Inc.NASDAQHealthcare$4.41+7.04%ClosedMarket Cap: $8.3M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.66
P/S
0.99
EV/EBITDA
0.02
DCF Value
$85.19
FCF Yield
920.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.7%
Operating Margin
-13713.7%
Net Margin
-4546.6%
ROE
-1538.3%
ROA
-1020.1%
ROIC
-1466.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $1.9M | $-0.77 |
| Q1 2026 | $0.00 | $-15.0M | $-6.67 |
| Q4 2025 | $-15.7M | $-378.1M | $-6.77 |
| FY 2025 | $24.0M | $-565.8K | $-0.23 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2025-12-05Maxim GroupBuy
2025-09-11HC Wainwright & Co.Buy
2025-08-26Trading Activity
Insider Trades
View AllWilson David Iandirector
SellWed Jan 21
Davies Peter Miles Winstondirector
SellWed Jan 21
Fisher Alandirector
SellWed Jan 21
Ryan Janedirector
SellWed Jan 21
Lynx1 Capital Management LP10 percent owner
BuyThu Oct 23
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.51
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.